Page 157 - First Aid for the USMLE Step 1 2020, Thirtieth edition [MedicalBooksVN.com]_Neat
P. 157

Immunology  ` Immunology—Immune reSponSeS       Immunology  ` Immunology—Immune reSponSeS             SECTIon II       113




                  Hypersensitivity types (continued)
                   Type III              Immune complex—antigen-antibody (mostly   In type III reaction, imagine an immune
                    hypersensitivity      IgG) complexes activate complement, which   complex as 3 things stuck together: antigen-
                                          attracts neutrophils; neutrophils release   antibody-complement.
                                          lysosomal enzymes.                      Examples:
                                         Can be associated with vasculitis and systemic     ƒ SLE

                         Neutrophils      manifestations.                             ƒ Polyarteritis nodosa
                                                                                      ƒ Poststreptococcal glomerulonephritis
                                         Serum sickness—the prototypic immune     Fever, urticaria, arthralgia, proteinuria,
                                          complex disease. Antibodies to foreign proteins   lymphadenopathy occur 1–2 weeks after
                                          are produced and 1–2 weeks later, antibody-  antigen exposure. Serum sickness-like
                                          antigen complexes form and deposit in tissues   reactions are associated with some drugs (may
                            Enzymes from
                            neutrophils   Ž complement activation Ž inflammation   act as haptens, eg, penicillin) and infections
                            damage        and tissue damage.                       (eg, hepatitis B).
                            endothelial cells
                                         Arthus reaction—a local subacute immune
                                          complex-mediated hypersensitivity reaction.
                                          Intradermal injection of antigen into a
                                          presensitized (has circulating IgG) individual
                                          leads to immune complex formation in the
                                          skin (eg, enhanced local reaction to a booster
                                          vaccination). Characterized by edema,
                                          necrosis, and activation of complement.
                   Type IV               Two mechanisms, each involving T cells:  Response does not involve antibodies (vs types I,
                    hypersensitivity                                               II, and III).
                                           1. Direct cell cytotoxicity: CD8+ cytotoxic T   Examples: contact dermatitis (eg, poison ivy,
                         A Antigen-           cells kill targeted cells.           nickel allergy) and graft-versus-host disease.
                         presenting cell
                                           2. Inflammatory reaction: effector CD4+   Tests: PPD for TB infection; patch test for
                                              T cells recognize antigen and release   contact dermatitis; Candida skin test for T cell
                    Antigen
                                              inflammation-inducing cytokines (shown   immune function.
                                              in illustration).                   4T’s: T cells, Transplant rejections, TB skin
                    Sensitized                                                      tests, Touching (contact dermatitis).
                     Th1 cell
                           Cytokines
                                                                                  Fourth (type) and last (delayed).






                              Delayed-type
                              hypersensitivity
                    Activated
                    macrophage
























          FAS1_2019_02-Immunology.indd   113                                                                            11/7/19   3:24 PM
   152   153   154   155   156   157   158   159   160   161   162